Anakinra for the treatment of adult-onset Still’s disease

References

• Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54:587–590.
   PubMed Web of Science ®Google Scholar
• Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol. 2006;35:48–51.
   PubMed Web of Science ®Google Scholar
• Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30:222–238.
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Esdaile JM, Medsger TA Jr, et al. A controlled study of the long-term prognosis of adult Still’s disease. Am J Med. 1995;98:384–388.
   PubMed Web of Science ®Google Scholar
• Cagatay Y, Gul A, Cagatay A, et al. Adult-onset Still’s disease. Int J Clin Pract. 2009;63:1050–1055.
   PubMed Web of Science ®Google Scholar
• Giampietro C, Fautrel B. Anti-Interleukin-1 agents in adult onset Still’s disease. Int J Inflam. 2012;2012:317820.
   PubMedGoogle Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53–62.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–722.
   PubMed Web of Science ®Google Scholar
• Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149–1159.
   PubMed Web of Science ®Google Scholar
• Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31:47–52.
   PubMed Web of Science ®Google Scholar
• Castañeda S, Vicente EF, González-Gay MA. Adult-onset Still’s disease. Med Clin (Barc). 2016;147: 217–222. Review. Spanish.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Le Moël G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol. 2001;28:322–329.
   PubMed Web of Science ®Google Scholar
• Vignes S, Le Moël G, Fautrel B, et al. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still’s disease. Ann Rheum Dis. 2000;59:347–350.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305–314.
   PubMed Web of Science ®Google Scholar
• Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–2535.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–99.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26:373–378.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al.; Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
   PubMed Web of Science ®Google Scholar
• Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32:1291–1298.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Arlet J-B. Biological treatment in adult-onset Still’s disease. Best Pract Res Clin Rheumatol. 2012;26:477–487.
   PubMed Web of Science ®Google Scholar
• Puéchal X, DeBandt M, Berthelot J-M, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63:155–159.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33:49–55.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41:244–247.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659–1665.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G, et al. Response to Interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.
   PubMed Web of Science ®Google Scholar
• Lo Gullo A, Caruso A, Pipitone N, et al. Canakinumab in a case of adult onset Still’s disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81:376–377.
   PubMed Web of Science ®Google Scholar
• Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42:201–205.
   PubMed Web of Science ®Google Scholar
• Junge G, Mason J, Feist E. Adult onset Still’s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017;47:295–302.
   PubMed Web of Science ®Google Scholar
• Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668–675.
   PubMed Web of Science ®Google Scholar
• Néel A, Wahbi A, Tessoulin B, et al. Diagnostic and management of life-threatening adult-onset Still disease: a French nationwide multicenter study and systematic literature review. Crit Care. 2018;22:88.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81:194–200.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–136.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Devilliers H, Peng SL, et al. The relapsing polychondritis disease activity index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev. 2012;12:204–209.
   PubMed Web of Science ®Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdf
   Google Scholar
• Koné-Paut I, Piram M. Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: what did we learn? Autoimmun Rev. 2012;12:77–80.
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Galeotti C. Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2014;10:7–18.
   PubMed Web of Science ®Google Scholar
• Landmann EC, Walker UA. Pharmacological treatment options for cryopyrin-associated periodic syndromes. Expert Rev Clin Pharmacol. 2017;10:855–864.
   PubMed Web of Science ®Google Scholar
• Tran TA. Muckle-Wells syndrome: clinical perspectives. Open Access Rheumatol. 2017 Jul 11;9:123–129.
   PubMedGoogle Scholar
• Fenini G, Contassot E, French LE. Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases. Front Pharmacol. 2017;8:278.
   PubMed Web of Science ®Google Scholar
• Wikén M, Hallén B, Kullenberg T, et al. Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. Clin Rheumatol. 2018 Jul 7. DOI:10.1007/s10067-018-4196-x.
   PubMedGoogle Scholar
• Nordstrom D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008–2011.
   PubMed Web of Science ®Google Scholar
• Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–308.
   PubMed Web of Science ®Google Scholar
• Vasques Godinho FM, Parreira Santos MJ, Canas Da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Di. 2005;64:647–648.
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794–1803.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842–843.
   PubMed Web of Science ®Google Scholar
• Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189–197.
   PubMed Web of Science ®Google Scholar
• Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol. 2003;9:330–332.
   PubMed Web of Science ®Google Scholar
• Vitale A, Insalaco A, Sfriso P, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94:e1554.
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.
   PubMed Web of Science ®Google Scholar
• Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822–826.
   PubMed Web of Science ®Google Scholar
• Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13:R91.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol. 2015;44:309–314.
   PubMed Web of Science ®Google Scholar
• Dall’Ara F, Frassi M, Tincani A, et al. A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need? Clin Rheumatol. 2016;35:2117–2123.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Zuliani F, et al. Pleuritis is a red flag for adult-onset Still’s disease which may require biologic therapies. Clin Exp Rheumatol. 2012;30:807.
   PubMed Web of Science ®Google Scholar
• Naumann L, Feist E, Natusch A, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann Rheum Dis. 2010;69:466–467.
   PubMed Web of Science ®Google Scholar
• Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis. 2012;71:2056–2057.
   PubMed Web of Science ®Google Scholar
• Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis. 2011;70:390–392.
   PubMed Web of Science ®Google Scholar
• Priori R, Ceccarelli F, Barone F, et al. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still’s disease. Clin Exp Rheumatol. 2008;26:933–937.
   PubMed Web of Science ®Google Scholar
• Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140:784–790.
   PubMed Web of Science ®Google Scholar
• Cush JJ. Autoinflammatory syndromes. Dermatol Clin. 2013;31:471–480.
   PubMed Web of Science ®Google Scholar
• Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40:1398–1404.
   PubMed Web of Science ®Google Scholar
• Chen D-Y, Lan J-L, Lin F-J, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–2198.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Sève P, Hot A, et al. [Pathophysiology, subtypes, and treatments of adult-onset Still’s disease: an update]. Rev Med Interne. 2015;36:319–327.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Henry T, et al. Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag. 2014;11:33–43.
   PubMed Web of Science ®Google Scholar
• Yoo DH. Treatment of adult-onset still’s disease: up to date. Expert Rev Clin Immunol. 2017;13:849–866.
   PubMed Web of Science ®Google Scholar
• Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford). 2016;55:2237–2247.
   PubMed Web of Science ®Google Scholar
• Mitrovic S, Fautrel B. New markers for adult-onset still’s disease. Joint Bone Spine. 2018;85:285–293.
   PubMed Web of Science ®Google Scholar
• Feist E, Mitrovic S, Fautrel B. Adult onset Still’s disease. New Mechanisms, Biomarkers and Targets. Nat Rev Rheumatol. 2018 Oct;14(10):603–618.
   Google Scholar
• Guo Q, Zha X, Li C, et al. Serum calprotectin–a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol. 2016;35:73–79.
   PubMed Web of Science ®Google Scholar